⚠️ Important: About Your Medication
If you purchased the compounded GLP-1 medication, the medication you received from Bliv is a compounded GLP-1 prepared by a licensed compounding pharmacy. It is not a branded manufacturer product. It is not Ozempic®, Wegovy®, Mounjaro®, or Zepbound® — which are brand-name medications manufactured by Novo Nordisk and Eli Lilly respectively. Compounded medications are not FDA-approved finished drug products, though they are prepared under federal standards by licensed pharmacies. If you have questions about this distinction, please speak with your Bliv provider.

Bliv offers two compounded GLP-1 medications: compounded Semaglutide and compounded Tirzepatide. Both work by influencing hormones that regulate appetite and blood sugar. Both are administered as weekly subcutaneous injections. Both have been shown to produce meaningful, sustained weight loss in clinical use. The right choice for you depends on your medical profile and your provider's recommendation.

Neither is the same as a branded manufacturer product. They are not Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. They are compounded formulations of the same active pharmaceutical ingredients, prepared by a licensed compounding pharmacy under federal standards.

Compounded Semaglutide is a GLP-1 receptor agonist. It works by mimicking a hormone called GLP-1 that is naturally released after eating. This slows gastric emptying, reduces appetite, and signals the brain that you are full sooner. The result is a meaningful reduction in food intake and, over time, significant weight loss.

Semaglutide is typically the starting point for patients new to GLP-1 therapy due to its well-established profile and generally favorable tolerability.

Compounded Tirzepatide is a dual GLP-1 and GIP receptor agonist. In addition to the GLP-1 mechanism described above, Tirzepatide also activates GIP receptors — a second gut hormone pathway that works alongside GLP-1 to further reduce appetite and improve metabolic function. This dual action is why clinical data has generally shown greater average weight loss with Tirzepatide compared to Semaglutide alone.

Tirzepatide is often recommended for patients who have not achieved their goals on Semaglutide, or for patients whose provider believes the dual mechanism is the better starting point based on their health profile.

This is a clinical decision made between you and your Bliv provider based on your health history, goals, and how you respond to treatment. Generally speaking, the tirzepatide does produce faster and a little better results. On the other hand, the semaglutide also has great results and is cheaper.